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Summary 
CD40 is a member of the tumor necrosis factor (TNF) receptor family of cell surface proteins 
and was originally described as a B cell restricted antigen. Treatment of primary human monocytes 
with granulocyte/macrophage colony-stimulating factor (GM-CSF),  interleukin 3  (IL-3),  or 
interferon 3' (IFN-3') resulted in the induction of CD40 mRNA and enhancement of cell surface 
protein expression. CD40 was found to mediate monocyte adhesion to cells expressing recombinant 
CD40 ligand. CD40 ligand-transfected cells provided a potent costimulus for monocyte TNF-ot 
and IL-6 production in the presence of GM-CSF, IL-3, or IFN-3', and enhanced IL-8 production 
stimulated by GM-CSF or IL-3. In addition, CD40 ligand-transfected cells acting in the absence 
of a costimulus induced monocytes to become tumoricidal against a human mdanoma cell target. 
Collectively, these data indicate that CD40 ligand is pleiotropic with potent biological activity 
on monocytes. 
C 
D40 is a 50-kD molecule expressed on B cells, dendritic 
cells, some carcinoma cell lines, and human thymic epi- 
thelium (1-3).  Abs  specific for CD40  exhibit stimulatory 
effects on IL-4 activated B cells, including the induction of 
B cell growth, IgE secretion, and expression of CD23 (4-7). 
Human and murine forms of a ligand for CD40 (CD40L) 1 
were recently cloned and demonstrated to be type II integral 
membrane proteins expressed primarily on activated CD4 + 
T cells (8-11). CD40L provides a strong stimulatory signal 
to B cells from both species (8-10), however little is known 
about the regulation of expression of CD40 and the effects 
of CD40L on other cell types. 
Monocytes express  a variety of cell surface proteins that 
are thought to play an important role in antigen presenta- 
tion and the cell contact-dependent interaction of monocytes 
with other leukocytes. The expression of many of these pro- 
teins on monocytes can be regulated by a variety of cytokines, 
including GM-CSF, IL-3, IL-4, IFN-3", and IFN-c~ (12-16). 
In this paper, we demonstrate that GM-CSF, IL-3, and IFN-'r 
enhance expression of CD40 by normal human monocytes. 
In addition, culture of monocytes with CD40L resulted in 
the stimulation or costimulation of cytokine production and 
in  the induction of monocyte tumoricidal activity. Thus, 
CD40L is involved in the regulation of several critical aspects 
1 Abbreviation used in this paper: L, ligand. 
of the immune response, and may be important in the cell 
contact-dependent activation of both T cells and monocytes 
during antigen presentation. 
Materials and Methods 
Monocyte Purification and Culture.  Monocytes were purified from 
normal donor PBMC by countercurrent elutriation (17) and were 
~95 % pure by microscopic  examination of Giemsa-stained  cytocen- 
trifuge preparations. Cells were cultured in RPMI 1640 medium 
containing 10% low endotoxin FBS, 50 U/ml penicillin, 50/zg/ml 
streptomycin, and 5  x  10 -s M 2-ME. Monocytes were cultured 
in polypropylene tubes (Falcon; Becton Dickinson Labware, Lin- 
coln Park, NJ) for flow cytometry and mRNA analysis, in 24-well 
plates (Costar Corp., Cambridge, MA) for cytokine secretion assays 
and in 96-well flat-bottomed plates (Costar Corp.) for adhesion 
and tumoricidal assays. 
Reagents.  All reagents used for culture ofmonocytes, including 
all media additives and cytokines, were screened for low endotoxin 
levels (<1 pg/ml at their final concentration) using the Limulus 
amebocyte lysate assay (Whittaker M.A. Bioproducts, Walkersvilh, 
MD).  Recombinant  CD40L  was  transiently  expressed in  CV- 
1/EBNA cells which were fixed  with paraformaldehyde 2 d after 
transfection, as described previously (8, 9). Recombinant 1I:3, II.-4, 
and GM-CSF were purified as described previously (16) and had 
sp act of 9  x  104, 1  x  104, and 5  x  104 U//zg, respectively. 
Soluble CD40 and IL-4R fusion proteins (CD40.Fc and ID4R.Fc) 
consisting of the extracellular domain of CD40 or IL-4R coupled 
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described previously (18). The murine  mAb  CD40 M2,  raised 
against soluble CD40.Fc, was demonstrated to block binding of 
CD40 ligand to CD40 (Fanslow, W. C., unpublished data). Pro- 
tein A-purified  G28-5 mAb recognizing human CD40 was provided 
by Dr. E. A.  Clark  (University of Washington,  Seattle, WA). 
Flow Cytoraetry.  Cells  were recovered  and incubated for 30 rain 
at 4QC in PBS containing 2% rabbit serum and 2% goat serum 
to block Fc receptor binding by detecting Ab. After washing once 
in PBS with 1% FBS and 0.02% sodium azide, cells  were incubated 
with the CD40 mAb G28-5 or isotype-matched control Ab (5 
/~g/ml) for 30 min at 4~  The cells were washed twice and in- 
cubated with sheep anti-mouse IgG-PE (F[ab']z fragment) for 30 
rain at 4~  After further washing, flow cytometric analysis was 
performed using a FACScan  # (Becton Dickinson & Co., Moun- 
tain View, CA). 
Northern Blot Analysis of CD40 mRNA.  Monocytes were har- 
vested, the RNA extracted, and samples from similar culture con- 
ditions pooled for electrophoresis on agarose formaldehyde gels (10 
/~g per lane), as described previously (17). Gels were transferred 
to nitrocellulose and probed with a 32p-labeled, PCR-generated 
probe corresponding  to the entire ending region of  the human CD40 
molecule. Control hybridizations were performed after blots were 
stripped by boiling in water and 1% SDS and exposed to  x-ray 
film to confirm removal of CD40 specific  probe. Blots were then 
rehybridized with a human  8-actin  probe. 
Monocyte Adhesion Assay.  The monocyte adhesion assay was 
based upon the method described by Elliot et al. (19). Monolayers 
of  CV-1/EBNA cells (20) transfected  with murine or human CD40L 
(CV1-MuCD4OL/HuCD4OL) or vector alone were established by 
incubating  3  x  104 cells in 96-well microtiter  plates for 6 h at 
37~  Monocytes were labeled with 150/zCi of SlCr for 1 h at 
37~  and washed three times. Labeled monocytes (10  s) were then 
added to the plates containing the monolayers of transfected cells 
and allowed to adhere for 24 h. Samples of supernatant were col- 
lected in order to assess spontaneous SlCr release, and wells were 
washed three times to remove nonbound cells. Residual adherent 
cells were lysed in 1% (wt/vol) NP-40 detergent and lysates were 
transferred to  tubes  for measurement  of S~Cr content using  a 
gamma counter (ME Plus; Micromedics, Huntsville, TN). Percent 
adhesion was calculated as 100  x  [adherent cpm/(total cpm  - 
spontaneous cpm)]. 
Cytokine Assays.  Cytokine production by monocytes was mea- 
sured by ELISA, as described previously (17). 
Monocyte-mediated Tumoricidal  Assay.  The assay for monocyte 
tumoricidal activity was modified from the one described previ- 
ously (17). Briefly,  monocytes  were cultured in 96-well  flat-bottomed 
plates in the presence of CV-1/EBNA cells that had been trans- 
fected with either CD40L or vector alone. After 24 h, culture su- 
pernatants were removed and replaced with target A375 cells and 
incubated for an additional 3 d. Culture plates were washed three 
times with medium and remaining adherent A375 cells were mea- 
sured by staining with crystal violet (0.5% wt/vol in 25% vol/vol 
methanol). After lysis with 1% (wt/vol) deoxycholate, OD at 562 
nm was determined using an ELISA  plate reader (Dynatech Labora- 
tories Inc., Chantilly, VA). Percent cytotoxicity was calculated as 
100  x  [1  -  (OD test  -  OD background/OD control -  OD 
background)],  where  OD  background  represents empty wells 
stained with crystal violet and washed, OD control represents wells 
with A375 cells cultured with untreated monocytes, and OD test 
represents wells with A375 cells cultured with monocytes together 
with CV-1/EBNA cells or soluble stimuli. 
Results and Discussion 
Regulation of  Monocyte Cell Surface CD40 Expression.  Pri- 
mary human monocytes were isolated by countercurrent elutri- 
ation and examined for cell surface expression of CD40 using 
flow cytometry. Freshly isolated monocytes or monocytes cul- 
tured in medium alone for 48 h typically expressed low but 
detectable CD40 surface protein, as assessed by indirect im- 
munofluorescent staining with the mAb G28-5 (Fig. 1). How- 
ever, upon culture for 48 h in GM-CSF, IL-3, or IFN-3', CD40 
expression by monocytes was markedly increased (Fig.  1). 
In contrast, IL-4 had little or no effect on CD40 expression 
by monocytes. Of the panel of cytokines tested (ILs 1-8 and 
10,  IFNs-c~ and -% TNF-o~, G-CSF, and GM-CSF), only 
GM-CSF, IL-3, and IFN-3' were found to consistently en- 
hance monocyte CD40 expression. 
Kinetics and Dose-Response of Enhancement of CD40 Expres- 
sion.  To further investigate the regulation of monocyte CD40 
by GM-CSF, IL-3, and IFN-'y, we analyzed the effects of 
titrating concentrations of cytokines and varying the stimu- 
lation period (Fig. 2). GM-CSF and IFN-3, enhanced CD40 
expression by monocytes when used at concentrations as low 
as 0.1 ng/ml, whereas 1 ng/ml of IL-3 was required. Op- 
timal enhancement of monocyte CD40 expression was ob- 
served at cytokine concentrations between 10 and 100 ng/ml. 
IL-4 had no significant effect on CD40 expression at any of 
the concentrations tested. Optimal induction of CD40 by 
GM-CSF, IL-3, or IFN-3, was seen at 24 h after stimulation 
and high levels of CD40 expression were maintained for an 
additional 48 h. 
Regulation of CD40 mRNA Transc@tion.  CD40 mRNA 
transcription was examined in primary monocytes  by Northern 
blot analysis. Representative levels of CD40 mRNA expres- 
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Figure  1.  Enhancement  of human monocyte  CD40 expression  by GM- 
CSF, Ib3, and IFN-% Monocytes  were cultured with various cytokines 
(10 ng/ml) for 48 h and analyzed  for CD40 expression  by flow  cytometry. 
The numbers in parentheses represent mean fluorescent  intensity (MFI) 
of staining with G28-5 minus that of control isotype staining, and are 
expressed in arbitrary  log units. The data are from one of five  representa- 
tive experiments performed. 
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Figure 2.  Dose-response  and kinetics of enhancement  of monocyte 
CD40 expression by ~tokines. (A) Mono~tes were stimulated with var- 
ious concentrations of GM-CSF, Ib3, IL-4, or IFN-3~  for 24 h and assessed 
for CD40 expression by flow ~tometry. (B) Monocytes were stimulated 
for various time periods with the indicated cytokines at I0 ng/ml. 
sion in monocytes cultured with various cytokines are shown 
in Fig. 3 A. Little or no CD40 specific mRNA was seen 
in monocytes cultured in medium alone or in IL-4. In con- 
trast,  monocytes treated with  IFN-%  GM-CSF,  or  IL-3 
showed relatively abundant levels of CD40 mRNA (Fig. 3 
A), which did not increase significantly in monocytes cul- 
tured with combinations of GM-CSF, IL-3, and IFN-y (data 
not shown). These results indicate that the increased  cell surface 
expression of CD40 in response to these cytokines (Fig. 1) 
is likely a result  of increased CD40 mRNA transcription. 
Adhesion of  Monocytes to Cells 7~ansfected  with CD4OL.  The 
surface expression of CD40 by monocytes suggests a pos- 
sible role for this protein in cell contact-dependent interac- 
tions of monocytes with cells expressing CD40L. Initially, 
monocytes were examined for their ability to adhere to cells 
expressing recombinant CD40L. For these experiments we 
used CV-1/EBNA cells (20) that had been transfected with 
full-length membrane-bound murine or human CD40L (8, 
9), or control CV-1/EBNA cells transfected with the vector 
alone. Monocytes were found to adhere far more efficiently 
to CV-1/EBNA cells expressing either murine or human 
CD40L than to cells transfected with vector alone (Fig. 4). 
As virtually all the monocytes adhered to CV-1/EBNA cells 
expressing CD40L, addition of  GM-CSF, IL-3, or IFN-3, was 
unable  to  further enhance monocyte adhesion  (data  not 
shown). The adhesion was shown to be mediated by CD40 
Figure 3.  Regulation of CD40 transcription in cytokine-treated pri- 
mary monocytes. Monocytes purified from three human donors were cul- 
tured independently  for 18 h with no treatment (NT) or with the indi- 
cated cytokines at t0 ng/ml. The EBV-transformed B lymphoblastoid cell 
line RPMI 1788 stimulated with the phorbol ester, PMA (1788.PMA) 
was included as a positive control.  Northern blots were hybridized with 
a probe for (/1) CD40 and (B)/~-actin  (hybridization  control). 
binding to CD40L since a mAb to CD40, but not an isotype 
control mAb, blocked binding of  monocytes to CV-1/EBNA 
cells transfected with CD40L (Fig. 4 B). 
CD40L Stimulates Monocyte Cytokine Production.  Cyto- 
kines, such as TNF-c~, IL-1, and IL-6, are released  from mono- 
cytes during antigen presentation  (21). Thus, it was of in- 
terest to determine whether cells transfected with CD40L 
could induce or coinduce the release of monocyte cytokines. 
CV-1/EBNA cells expressing recombinant CD40L induced 
monocytes to secrete small amounts of IL-6 and enhanced 
the release of IL-8 in the absence of a costimulus,  whereas 
control CV-1/EBNA cells had no effect (Fig. 5, A  and B). 
In contrast, CD40L acting alone was unable to induce TNF-o~ 
production (Fig. 5 C). 
GM-CSF, IL-3, and IFN-3' have  all been demonstrated to 
costimulate cytokine production by monocytes (22, 23). In 
addition,  GM-CSF and IL-3 were recently demonstrated to 
enhance IL-8  release by  monocytes in  the  absence of a 
costimulus  (24). Since these  three cytokines  also enhance 
monocyte CD40 expression, we assessed the effect of  CD40L 
on monocyte cytokine production in the presence of these 
costimulatory cytokines. The combination of CD40L with 
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Figure  4.  Adhesion  of  monocytes  to  cells  expressing  recombinant 
CD4OL.  Data are mean  +  SD of six replicates and are representative of 
four experiments  performed.  Nil, percent adhesion of monocytes to the 
wells alone.  CD40 mAb M2 and IgG1 isotype control  mAb were used 
at  10 #g/ml. 
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Figure  5.  CD40L stimulates  monocyte Ib6 and lb8 production  (A 
and B) and costimuhtes TNF-ot production with GM-CSF, Ib3, or IFN-7 
(C).  Monocytes  were cultured  at 5  x  10  s cells/ml in 24-well plates ei- 
ther alone or with paraformaldehyde-fixed CV-1/EBNA cells (3  x  104) 
that had been transfected with human CD40L or vector alone. Cytokines 
were added at 10 ng/ml. After 24 h, supernatants were recovered and as- 
sessed for IL-6, IL-8, and TNF-~ levels by ELISA. 
GM-CSF,  IL-3,  or IFN-3' was a potent stimulus  for both 
IL-6 and TNF-o~ production, whereas these cytokines acting 
alone had little effect (Fig. 5, A  and C). As few as 103 CV- 
1/EBNA cells expressing CD40L were sufficient to induce 
TNF-~  production  in the presence of GM-CSF,  IL-3,  or 
IFN-% yet even large numbers of these cells alone were un- 
able to induce significant TNF-c~ production (Fig. 6 A). GM- 
CSF or IL-3 induced an approximate llYfold increase in mono- 
cyte IL-8 production when acting alone, and this effect was 
further enhanced twofold by the presence of CD40L (Fig. 
5 B).  In contrast, IFN-3' did not enhance IL-8 secretion in 
the presence or absence of CD40L. CD40L also failed to con- 
sistently stimulate or costimulate IL-1 release, with detect- 
able IL-1 levels observed in only one of six experiments (data 
not shown). The specificity of the CD40L effect was confirmed 
using a soluble construct of CD40 consisting of the extracel- 
lular domain of CD40 fused to the Fc region of human IgG1 
(CD40.Fc) (18), as well as an antagonistic CD40 mAb, M2 
(see  Materials and Methods),  which  were  able to inhibit 
TNF-c~ production  induced by CD40L in the presence of 
GM-CSF  (Fig. 6 B).  An isotype  control mAb and human 
IgG1 were unable to block TNF-c~ production in this assay. 
TNF-~ is a cytokine with a central role in inflammation, 
and thus CD40L may have pro-inflammatory properties in 
conjunction  with other  cytokines  via its costimulation  of 
TNF-c~. IL-6 has growth and differentiation activity on mul- 
tiple cell types and stimulates the release of acute phase pro- 
teins by hepatocytes. Recent studies have demonstrated that 
IL-8 inhibits IgE production by purified B cells stimulated 
with CD40 mAb in combination  with IL-4 (25).  Thus,  it 
is tempting to speculate that the ability of CD40L to stimu- 
late IL-8 production by monocytes represents a negative feed- 
back mechanism for the control  of IgE production. 
CD40L Induces Monocyte Tumoricidal  Activity.  Monocytes 
can be stimulated by certain cytokines  to become tumori- 
cidal against selected tumor cell lines. Incubation of mono- 
cytes with CV-1/EBNA cells expressing recombinant CD40L 
resulted in the activation of tumoricidal activity against the 
A375 human melanoma cell line (Table 1). The activity of 
CD40L in this assay was equivalent to that of LPS. CD40L 
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Figure  6.  (.4) Dose-response of CD40L induction of TNF-ct produc- 
tion. Monocyte cultures were established with increasing numbers of CV- 
1/EBNA cells expressing CD40L either alone or in the presence of GM- 
CSF, Ib3, or IFN-'Ir (10 ng/ml), and TNF-ot levels were detected at 24 h 
by ELISA. (/3) CD40L-induced TNF-ot production is inhibited by CD40.Fc 
or CD40 mAb. Monocytes were stimulated with CD40L in the presence 
of GM-CSF. CD40.Ec,  CD40 mAb M2, control Fc, and isotype control 
mAb were used at a final concentration of 10/~g/ml. TNF-~ was non- 
detectable (<5 pg/ml) in control cultures with medium alone, GM-CSF 
alone,  CD40L alone,  CD40.Fc alone,  or CD40 antibody alone. 
caused a small but insignificant enhancement in monocyte 
tumoricidal activity induced by GM-CSF. Control or CD40L 
transfected CV-1/EBNA cells had no lytic activity against 
A375 targets in the absence of monocytes (data not shown). 
Monocyte secretion of TNF-c~ and IL-1 in response to stimuli 
such as LPS has been demonstrated to contribute to their 
tumoricidal activity (26-28).  Given that CD40L  alone is 
insufficient for the rdease of either TNF-oe or IL-1 from mono- 
cytes, the data suggest that CD40L may regulate monocyte 
tumoricidal activity through an IL-1/TNF-c~ independent 
mechanism. Alternatively, CD40L may induce monocytes to 
Table  1.  CD40L Induces Monocyte Tumoricidal Activity 
Percent  cytotoxicity 
Stimulus  Expt.  1  Expt.  2 
CV-1  control  -  9.3  -  4.2 
CV-1  CD40L  63.4  _+  9.8  64.1  _+  8.8 
LPS  67.1  _+  8.3  59.5  +  11.8 
GM-CSF  56.9  _+  4.9  53.6  _+  3.7 
GM-CSF+CV-1  CD40L  62.2  _+  14.1  70.5  +  13.0 
Date represent  percent  cytotoxicity of monocytes cultured with various 
stimuli  as  compared  with  monocytes cultured  in  medium  alone  and 
represent mean _  SD of six replicate welts. LPS was used at 10/~g/ml, 
GM-CSF at  10 ng/ml, and  CV-1/EBNA cells at  104 per well. 
express cell surface, but not soluble,  IL-1 or TNF-ot, and 
experiments are currently aimed at addressing this possibility. 
Previous data has suggested that CD40-CD40L  interac- 
tions are a critical component of the interaction between helper 
T cells and B cells in the immune response (4-10). The data 
presented here suggest that CD40-CD40L interactions may 
also play an important role in the cell contact-dependent in- 
teraction that occurs between activated  helper T  cells and 
monocytes/macrophages  during antigen presentation.  Impor- 
tantly, an efficient way of inducing CD40L expression by 
CD4 + T cells is via triggering through the CD3 TCR com- 
plex using either Ab against CD3 or antigen (8, 9; Alderson, 
M. IL., and R. J. Armitage, unpublished data). The interac- 
tion of the APC with the T cell results in the release of T 
cell-derived cytokines, including GM-CSF, IL-3, and IFN-% 
which would then be capable of regulating CD40 expression 
by the monocyte. Enhanced expression of CD40 by the mono- 
cyte could allow for increased stimulation by the T cell-ex- 
pressed CD40L, which would then give rise to further acti- 
vation  of the monocyte and  release of monocyte-derived 
cytokines. Thus, the interaction between monocytes and T 
cells during antigen presentation involves a cascade of activa- 
tion events,  of which CD40-CD40L  interactions may be 
critical. 
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